Contemporary Outcomes After Endovascular Treatment for Aorto-Iliac Artery Disease
Background: The patency and complications in aorto-iliac (AI) stenting remain poorly understood. The aim of this paper was to investigate the safety and efficacy after AI stenting. Methods and Results: This study was performed as a large-scale multicenter, retrospective registry. A total of 2,147 co...
Gespeichert in:
| Veröffentlicht in: | Circulation Journal 2012, Vol.76(11), pp.2697-2704 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2704 |
|---|---|
| container_issue | 11 |
| container_start_page | 2697 |
| container_title | Circulation Journal |
| container_volume | 76 |
| creator | Soga, Yoshimitsu Iida, Osamu Kawasaki, Daizo Yamauchi, Yasutaka Suzuki, Kenji Hirano, Keisuke Koshida, Ryoji Kamoi, Daisuke Tazaki, Junichi Higashitani, Michiaki Shintani, Yoshiaki Yamaoka, Terutoshi Okazaki, Shinya Suematsu, Nobuhiro Tsuchiya, Taketsugu Miyashita, Yusuke Shinozaki, Norihiko Takahashi, Hiroki on behalf of REAL-AI investigators |
| description | Background: The patency and complications in aorto-iliac (AI) stenting remain poorly understood. The aim of this paper was to investigate the safety and efficacy after AI stenting. Methods and Results: This study was performed as a large-scale multicenter, retrospective registry. A total of 2,147 consecutive patients with AI disease were enrolled. The safety endpoints were procedure success, complications and 30-day mortality. The efficacy endpoints were primary, assisted primary and secondary patency, overall survival, freedom from major adverse cardiovascular events (MACE; all-cause death, myocardial infarction and stroke), and major adverse cardiovascular and limb events (MACLE; any repeat revascularization for limb and leg amputation in addition to MACE). Procedure success, complication rate and 30-day mortality were 97.6%, 6.4% and 0.7%. Primary patency was 92.5%, 82.6% and 77.5% at 1, 3 and 5 years, assisted primary patency was 97.0%, 92.7% and 91.9% at 1, 3 and 5 years and secondary patency was 99.0%, 98.7% and 98.5% at 1, 3 and 5 years. The overall survival rate was 95.0%, 87.6%, and 79.3% at 1, 3 and 5 years. The cause of death was cardiovascular in 44.1%. Freedom from MACE (MACLE) was 93.3% (89.9%), 84.4% (76.7%), and 74.9% (66.8%) at 1, 3 and 5 years. Female gender, diabetes, renal failure, absence of aspirin, reference vessel diameter |
| doi_str_mv | 10.1253/circj.CJ-12-0492 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1273155870</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1273155870</sourcerecordid><originalsourceid>FETCH-LOGICAL-c643t-a513ee0bc2f62363b7a72215aa61438cd47a1ec82d07881bd19719520a44e0c53</originalsourceid><addsrcrecordid>eNpFkMtLw0AQhxdRtD7uniRHL9F9Jbs5llirIoig52W6mWhKkq27G6H_vamt9jIP-OYH8xFyyegN45m4tY23y5vyKWU8pbLgB2TChFSp1Jwe_s55WmgpTshpCEtKeUGz4piccK5zyZWekNfS9RG7lfPg18nLEK3rMCTTOqJPZn3lviHYoQWfvHmE2GEfk9r5ZOp8dOlj24BNpn6E18ldExACnpOjGtqAF7t-Rt7vZ2_lQ_r8Mn8sp8-pzaWIKWRMINKF5XXORS4WChTnLAPImRTaVlIBQ6t5RZXWbFGxQrEi4xSkRGozcUaut7kr774GDNF0TbDYttCjG4JhXAmWZVrREaVb1HoXgsfarHzTjQ8bRs1GpPkVacqncTMbkePJ1S59WHRY_R_8mRuB-RZYhggf-A-Aj41tcZeocsPYpu6j98QneIO9-AFL9YjZ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1273155870</pqid></control><display><type>article</type><title>Contemporary Outcomes After Endovascular Treatment for Aorto-Iliac Artery Disease</title><source>MEDLINE</source><source>J-STAGE (Japan Science & Technology Information Aggregator, Electronic) Freely Available Titles - Japanese</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Soga, Yoshimitsu ; Iida, Osamu ; Kawasaki, Daizo ; Yamauchi, Yasutaka ; Suzuki, Kenji ; Hirano, Keisuke ; Koshida, Ryoji ; Kamoi, Daisuke ; Tazaki, Junichi ; Higashitani, Michiaki ; Shintani, Yoshiaki ; Yamaoka, Terutoshi ; Okazaki, Shinya ; Suematsu, Nobuhiro ; Tsuchiya, Taketsugu ; Miyashita, Yusuke ; Shinozaki, Norihiko ; Takahashi, Hiroki ; on behalf of REAL-AI investigators</creator><creatorcontrib>Soga, Yoshimitsu ; Iida, Osamu ; Kawasaki, Daizo ; Yamauchi, Yasutaka ; Suzuki, Kenji ; Hirano, Keisuke ; Koshida, Ryoji ; Kamoi, Daisuke ; Tazaki, Junichi ; Higashitani, Michiaki ; Shintani, Yoshiaki ; Yamaoka, Terutoshi ; Okazaki, Shinya ; Suematsu, Nobuhiro ; Tsuchiya, Taketsugu ; Miyashita, Yusuke ; Shinozaki, Norihiko ; Takahashi, Hiroki ; on behalf of REAL-AI investigators ; REAL-AI investigators</creatorcontrib><description>Background: The patency and complications in aorto-iliac (AI) stenting remain poorly understood. The aim of this paper was to investigate the safety and efficacy after AI stenting. Methods and Results: This study was performed as a large-scale multicenter, retrospective registry. A total of 2,147 consecutive patients with AI disease were enrolled. The safety endpoints were procedure success, complications and 30-day mortality. The efficacy endpoints were primary, assisted primary and secondary patency, overall survival, freedom from major adverse cardiovascular events (MACE; all-cause death, myocardial infarction and stroke), and major adverse cardiovascular and limb events (MACLE; any repeat revascularization for limb and leg amputation in addition to MACE). Procedure success, complication rate and 30-day mortality were 97.6%, 6.4% and 0.7%. Primary patency was 92.5%, 82.6% and 77.5% at 1, 3 and 5 years, assisted primary patency was 97.0%, 92.7% and 91.9% at 1, 3 and 5 years and secondary patency was 99.0%, 98.7% and 98.5% at 1, 3 and 5 years. The overall survival rate was 95.0%, 87.6%, and 79.3% at 1, 3 and 5 years. The cause of death was cardiovascular in 44.1%. Freedom from MACE (MACLE) was 93.3% (89.9%), 84.4% (76.7%), and 74.9% (66.8%) at 1, 3 and 5 years. Female gender, diabetes, renal failure, absence of aspirin, reference vessel diameter <8.0mm and outflow lesion were found to be independent predictors of primary patency. Conclusions: The safety and efficacy after AI stenting are feasible compared to surgical reconstruction. (Circ J 2012; 76: 2697–2704)</description><identifier>ISSN: 1346-9843</identifier><identifier>EISSN: 1347-4820</identifier><identifier>DOI: 10.1253/circj.CJ-12-0492</identifier><identifier>PMID: 22864278</identifier><language>eng</language><publisher>Japan: The Japanese Circulation Society</publisher><subject>Aged ; Aortic Diseases - mortality ; Aortic Diseases - physiopathology ; Aortic Diseases - surgery ; Aorto-iliac disease ; Blood Vessel Prosthesis Implantation ; Disease-Free Survival ; Endovascular Procedures ; Endovascular therapy ; Female ; Humans ; Iliac Artery ; Male ; Middle Aged ; Patency ; Registries ; Retrospective Studies ; Sex Factors ; Stents ; Survival Rate ; Time Factors ; Vascular Patency</subject><ispartof>Circulation Journal, 2012, Vol.76(11), pp.2697-2704</ispartof><rights>2012 THE JAPANESE CIRCULATION SOCIETY</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c643t-a513ee0bc2f62363b7a72215aa61438cd47a1ec82d07881bd19719520a44e0c53</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,1877,4010,27900,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22864278$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Soga, Yoshimitsu</creatorcontrib><creatorcontrib>Iida, Osamu</creatorcontrib><creatorcontrib>Kawasaki, Daizo</creatorcontrib><creatorcontrib>Yamauchi, Yasutaka</creatorcontrib><creatorcontrib>Suzuki, Kenji</creatorcontrib><creatorcontrib>Hirano, Keisuke</creatorcontrib><creatorcontrib>Koshida, Ryoji</creatorcontrib><creatorcontrib>Kamoi, Daisuke</creatorcontrib><creatorcontrib>Tazaki, Junichi</creatorcontrib><creatorcontrib>Higashitani, Michiaki</creatorcontrib><creatorcontrib>Shintani, Yoshiaki</creatorcontrib><creatorcontrib>Yamaoka, Terutoshi</creatorcontrib><creatorcontrib>Okazaki, Shinya</creatorcontrib><creatorcontrib>Suematsu, Nobuhiro</creatorcontrib><creatorcontrib>Tsuchiya, Taketsugu</creatorcontrib><creatorcontrib>Miyashita, Yusuke</creatorcontrib><creatorcontrib>Shinozaki, Norihiko</creatorcontrib><creatorcontrib>Takahashi, Hiroki</creatorcontrib><creatorcontrib>on behalf of REAL-AI investigators</creatorcontrib><creatorcontrib>REAL-AI investigators</creatorcontrib><title>Contemporary Outcomes After Endovascular Treatment for Aorto-Iliac Artery Disease</title><title>Circulation Journal</title><addtitle>Circ J</addtitle><description>Background: The patency and complications in aorto-iliac (AI) stenting remain poorly understood. The aim of this paper was to investigate the safety and efficacy after AI stenting. Methods and Results: This study was performed as a large-scale multicenter, retrospective registry. A total of 2,147 consecutive patients with AI disease were enrolled. The safety endpoints were procedure success, complications and 30-day mortality. The efficacy endpoints were primary, assisted primary and secondary patency, overall survival, freedom from major adverse cardiovascular events (MACE; all-cause death, myocardial infarction and stroke), and major adverse cardiovascular and limb events (MACLE; any repeat revascularization for limb and leg amputation in addition to MACE). Procedure success, complication rate and 30-day mortality were 97.6%, 6.4% and 0.7%. Primary patency was 92.5%, 82.6% and 77.5% at 1, 3 and 5 years, assisted primary patency was 97.0%, 92.7% and 91.9% at 1, 3 and 5 years and secondary patency was 99.0%, 98.7% and 98.5% at 1, 3 and 5 years. The overall survival rate was 95.0%, 87.6%, and 79.3% at 1, 3 and 5 years. The cause of death was cardiovascular in 44.1%. Freedom from MACE (MACLE) was 93.3% (89.9%), 84.4% (76.7%), and 74.9% (66.8%) at 1, 3 and 5 years. Female gender, diabetes, renal failure, absence of aspirin, reference vessel diameter <8.0mm and outflow lesion were found to be independent predictors of primary patency. Conclusions: The safety and efficacy after AI stenting are feasible compared to surgical reconstruction. (Circ J 2012; 76: 2697–2704)</description><subject>Aged</subject><subject>Aortic Diseases - mortality</subject><subject>Aortic Diseases - physiopathology</subject><subject>Aortic Diseases - surgery</subject><subject>Aorto-iliac disease</subject><subject>Blood Vessel Prosthesis Implantation</subject><subject>Disease-Free Survival</subject><subject>Endovascular Procedures</subject><subject>Endovascular therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Iliac Artery</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Patency</subject><subject>Registries</subject><subject>Retrospective Studies</subject><subject>Sex Factors</subject><subject>Stents</subject><subject>Survival Rate</subject><subject>Time Factors</subject><subject>Vascular Patency</subject><issn>1346-9843</issn><issn>1347-4820</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkMtLw0AQhxdRtD7uniRHL9F9Jbs5llirIoig52W6mWhKkq27G6H_vamt9jIP-OYH8xFyyegN45m4tY23y5vyKWU8pbLgB2TChFSp1Jwe_s55WmgpTshpCEtKeUGz4piccK5zyZWekNfS9RG7lfPg18nLEK3rMCTTOqJPZn3lviHYoQWfvHmE2GEfk9r5ZOp8dOlj24BNpn6E18ldExACnpOjGtqAF7t-Rt7vZ2_lQ_r8Mn8sp8-pzaWIKWRMINKF5XXORS4WChTnLAPImRTaVlIBQ6t5RZXWbFGxQrEi4xSkRGozcUaut7kr774GDNF0TbDYttCjG4JhXAmWZVrREaVb1HoXgsfarHzTjQ8bRs1GpPkVacqncTMbkePJ1S59WHRY_R_8mRuB-RZYhggf-A-Aj41tcZeocsPYpu6j98QneIO9-AFL9YjZ</recordid><startdate>2012</startdate><enddate>2012</enddate><creator>Soga, Yoshimitsu</creator><creator>Iida, Osamu</creator><creator>Kawasaki, Daizo</creator><creator>Yamauchi, Yasutaka</creator><creator>Suzuki, Kenji</creator><creator>Hirano, Keisuke</creator><creator>Koshida, Ryoji</creator><creator>Kamoi, Daisuke</creator><creator>Tazaki, Junichi</creator><creator>Higashitani, Michiaki</creator><creator>Shintani, Yoshiaki</creator><creator>Yamaoka, Terutoshi</creator><creator>Okazaki, Shinya</creator><creator>Suematsu, Nobuhiro</creator><creator>Tsuchiya, Taketsugu</creator><creator>Miyashita, Yusuke</creator><creator>Shinozaki, Norihiko</creator><creator>Takahashi, Hiroki</creator><creator>on behalf of REAL-AI investigators</creator><general>The Japanese Circulation Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>2012</creationdate><title>Contemporary Outcomes After Endovascular Treatment for Aorto-Iliac Artery Disease</title><author>Soga, Yoshimitsu ; Iida, Osamu ; Kawasaki, Daizo ; Yamauchi, Yasutaka ; Suzuki, Kenji ; Hirano, Keisuke ; Koshida, Ryoji ; Kamoi, Daisuke ; Tazaki, Junichi ; Higashitani, Michiaki ; Shintani, Yoshiaki ; Yamaoka, Terutoshi ; Okazaki, Shinya ; Suematsu, Nobuhiro ; Tsuchiya, Taketsugu ; Miyashita, Yusuke ; Shinozaki, Norihiko ; Takahashi, Hiroki ; on behalf of REAL-AI investigators</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c643t-a513ee0bc2f62363b7a72215aa61438cd47a1ec82d07881bd19719520a44e0c53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Aged</topic><topic>Aortic Diseases - mortality</topic><topic>Aortic Diseases - physiopathology</topic><topic>Aortic Diseases - surgery</topic><topic>Aorto-iliac disease</topic><topic>Blood Vessel Prosthesis Implantation</topic><topic>Disease-Free Survival</topic><topic>Endovascular Procedures</topic><topic>Endovascular therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Iliac Artery</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Patency</topic><topic>Registries</topic><topic>Retrospective Studies</topic><topic>Sex Factors</topic><topic>Stents</topic><topic>Survival Rate</topic><topic>Time Factors</topic><topic>Vascular Patency</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Soga, Yoshimitsu</creatorcontrib><creatorcontrib>Iida, Osamu</creatorcontrib><creatorcontrib>Kawasaki, Daizo</creatorcontrib><creatorcontrib>Yamauchi, Yasutaka</creatorcontrib><creatorcontrib>Suzuki, Kenji</creatorcontrib><creatorcontrib>Hirano, Keisuke</creatorcontrib><creatorcontrib>Koshida, Ryoji</creatorcontrib><creatorcontrib>Kamoi, Daisuke</creatorcontrib><creatorcontrib>Tazaki, Junichi</creatorcontrib><creatorcontrib>Higashitani, Michiaki</creatorcontrib><creatorcontrib>Shintani, Yoshiaki</creatorcontrib><creatorcontrib>Yamaoka, Terutoshi</creatorcontrib><creatorcontrib>Okazaki, Shinya</creatorcontrib><creatorcontrib>Suematsu, Nobuhiro</creatorcontrib><creatorcontrib>Tsuchiya, Taketsugu</creatorcontrib><creatorcontrib>Miyashita, Yusuke</creatorcontrib><creatorcontrib>Shinozaki, Norihiko</creatorcontrib><creatorcontrib>Takahashi, Hiroki</creatorcontrib><creatorcontrib>on behalf of REAL-AI investigators</creatorcontrib><creatorcontrib>REAL-AI investigators</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Circulation Journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Soga, Yoshimitsu</au><au>Iida, Osamu</au><au>Kawasaki, Daizo</au><au>Yamauchi, Yasutaka</au><au>Suzuki, Kenji</au><au>Hirano, Keisuke</au><au>Koshida, Ryoji</au><au>Kamoi, Daisuke</au><au>Tazaki, Junichi</au><au>Higashitani, Michiaki</au><au>Shintani, Yoshiaki</au><au>Yamaoka, Terutoshi</au><au>Okazaki, Shinya</au><au>Suematsu, Nobuhiro</au><au>Tsuchiya, Taketsugu</au><au>Miyashita, Yusuke</au><au>Shinozaki, Norihiko</au><au>Takahashi, Hiroki</au><au>on behalf of REAL-AI investigators</au><aucorp>REAL-AI investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Contemporary Outcomes After Endovascular Treatment for Aorto-Iliac Artery Disease</atitle><jtitle>Circulation Journal</jtitle><addtitle>Circ J</addtitle><date>2012</date><risdate>2012</risdate><volume>76</volume><issue>11</issue><spage>2697</spage><epage>2704</epage><pages>2697-2704</pages><issn>1346-9843</issn><eissn>1347-4820</eissn><abstract>Background: The patency and complications in aorto-iliac (AI) stenting remain poorly understood. The aim of this paper was to investigate the safety and efficacy after AI stenting. Methods and Results: This study was performed as a large-scale multicenter, retrospective registry. A total of 2,147 consecutive patients with AI disease were enrolled. The safety endpoints were procedure success, complications and 30-day mortality. The efficacy endpoints were primary, assisted primary and secondary patency, overall survival, freedom from major adverse cardiovascular events (MACE; all-cause death, myocardial infarction and stroke), and major adverse cardiovascular and limb events (MACLE; any repeat revascularization for limb and leg amputation in addition to MACE). Procedure success, complication rate and 30-day mortality were 97.6%, 6.4% and 0.7%. Primary patency was 92.5%, 82.6% and 77.5% at 1, 3 and 5 years, assisted primary patency was 97.0%, 92.7% and 91.9% at 1, 3 and 5 years and secondary patency was 99.0%, 98.7% and 98.5% at 1, 3 and 5 years. The overall survival rate was 95.0%, 87.6%, and 79.3% at 1, 3 and 5 years. The cause of death was cardiovascular in 44.1%. Freedom from MACE (MACLE) was 93.3% (89.9%), 84.4% (76.7%), and 74.9% (66.8%) at 1, 3 and 5 years. Female gender, diabetes, renal failure, absence of aspirin, reference vessel diameter <8.0mm and outflow lesion were found to be independent predictors of primary patency. Conclusions: The safety and efficacy after AI stenting are feasible compared to surgical reconstruction. (Circ J 2012; 76: 2697–2704)</abstract><cop>Japan</cop><pub>The Japanese Circulation Society</pub><pmid>22864278</pmid><doi>10.1253/circj.CJ-12-0492</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1346-9843 |
| ispartof | Circulation Journal, 2012, Vol.76(11), pp.2697-2704 |
| issn | 1346-9843 1347-4820 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1273155870 |
| source | MEDLINE; J-STAGE (Japan Science & Technology Information Aggregator, Electronic) Freely Available Titles - Japanese; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Aged Aortic Diseases - mortality Aortic Diseases - physiopathology Aortic Diseases - surgery Aorto-iliac disease Blood Vessel Prosthesis Implantation Disease-Free Survival Endovascular Procedures Endovascular therapy Female Humans Iliac Artery Male Middle Aged Patency Registries Retrospective Studies Sex Factors Stents Survival Rate Time Factors Vascular Patency |
| title | Contemporary Outcomes After Endovascular Treatment for Aorto-Iliac Artery Disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T20%3A48%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Contemporary%20Outcomes%20After%20Endovascular%20Treatment%20for%20Aorto-Iliac%20Artery%20Disease&rft.jtitle=Circulation%20Journal&rft.au=Soga,%20Yoshimitsu&rft.aucorp=REAL-AI%20investigators&rft.date=2012&rft.volume=76&rft.issue=11&rft.spage=2697&rft.epage=2704&rft.pages=2697-2704&rft.issn=1346-9843&rft.eissn=1347-4820&rft_id=info:doi/10.1253/circj.CJ-12-0492&rft_dat=%3Cproquest_cross%3E1273155870%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1273155870&rft_id=info:pmid/22864278&rfr_iscdi=true |